Blogs
Some molecules refuse to be easy to study. In this case, the drug was highly charged, sticky, and extremely sensitive to proteolysis, and previous partner labs had already struggled with it; “they’ve never seen anything like this before!” Keeping the entire process, from method transfer, optimization, validation, and…
Podcasts
The main discussion of this 30th episode of “The Conversational Flow” centers on automation in flow cytometry, focusing on a recent paper comparing three major sample preparation systems and their impact on efficiency, standardization, and error reduction. Our hosts, Adam and Brian, explore how automation can significantly reduce hands-on…
Blogs
Understanding Pharmacodynamics in Drug Development Pharmacodynamics (PD) examines the biochemical and physiological effects of drugs and the mechanisms behind those effects. While pharmacokinetics (PK) evaluates how the body processes a drug, pharmacodynamics focuses on how the drug affects the biological system. For bioanalytical scientists, the emphasis is…
webinars
Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…
Blogs
At KCAS Bio, we supported a therapeutic monoclonal antibody for advanced solid tumors from non-human primate (NHP) toxicology through first-in-human (FIH) dose escalation into phase 2 expansion. This project combined receptor occupancy assays (ROA) by flow cytometry for cell-surface binding on monocytes, immunophenotyping (IPT) for activation markers,…
Podcasts
In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to…
Blogs
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or…
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In…
News
KCAS Bio is proud to announce that its EU site (Lyon, France) has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP), confirming its ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. Our GLP test facility was granted a Level of compliance “A”, reinforcing KCAS Bio’s…
Podcasts
In episode #29 of “The Conversational Flow” podcast, our hosts, Brian and Adam, are joined by guests from Accelerating Cancer Immunotherapy Research (ACIR), a nonprofit dedicated to sharing important advances in cancer immunotherapy with the scientific community and the public. Ute Burkhardt discusses her background in cancer vaccines and…
Blogs
Reliable immune profiling across global studies depends on methods that perform consistently, regardless of where they are run. We address this question in the white paper entitled “Cross-Site Validation of a 15-Color Spectral Cytometry Panel for Leukocyte Profiling,” documenting a global collaboration between KCAS Bio and its strategic…
Posters & Papers
Discover in this white paper a global collaboration between KCAS Bio and its strategic partner, Crux Biolabs, to harmonize and validate a standardized 15-color spectral flow cytometry panel for pan-leukocyte profiling across multiple sites. If you have any questions about these services or any others…